Biotech Values

[DewDiligence]

BMEA -63%/AH on FDA clinical hold:

https://finance.yahoo.com/news/biomea-fusion-announces-bmf-219-200500839.html

…the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively.

The FDA cited deficiencies based on the level of possible drug-induced hepatotoxicity observed in the completed Dose Escalation Phase of COVALENT-111.